Oral-intestinal vaccines against diseases caused by enteropathic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
First Claim
Patent Images
1. A method for inducing an immune response in mammals comprising administering a pharmaceutical composition comprising an antigenic synthetic peptide containing CFA/I pilus protein T-cell epitopes encapsulated within a biodegradable polymeric matrix comprising poly (DL-lactide-co-glycolide) having a relative ratio between the amount of lactide and glycolide components within the range of 48:
- 52 to 58;
42, wherein the CFA-I pilus protein T-cell epitopes consist of the amino acid sequence;
(SEQ ID NO;
1) [4] (Asn-Ile-Thr-Val-Thr-Ala-Ser-Val-Asp-Pro),(SEQ ID NO;
11) (Gly-Asn-Tyr-Ser-Gly-Val-Val-Ser-Leu-Val), and mixtures thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
This invention is directed to oral-intestinal vaccines and their use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.
-
Citations
6 Claims
-
1. A method for inducing an immune response in mammals comprising administering a pharmaceutical composition comprising an antigenic synthetic peptide containing CFA/I pilus protein T-cell epitopes encapsulated within a biodegradable polymeric matrix comprising poly (DL-lactide-co-glycolide) having a relative ratio between the amount of lactide and glycolide components within the range of 48:
- 52 to 58;
42, wherein the CFA-I pilus protein T-cell epitopes consist of the amino acid sequence;(SEQ ID NO;
1) [4] (Asn-Ile-Thr-Val-Thr-Ala-Ser-Val-Asp-Pro),(SEQ ID NO;
11) (Gly-Asn-Tyr-Ser-Gly-Val-Val-Ser-Leu-Val), and mixtures thereof. - View Dependent Claims (2)
- 52 to 58;
-
3. A composition for inducing an immune response in mammals comprising of an antigenic synthetic peptide containing CFA-1 pilus protein T-Cell epitopes encapsulated within a biodegradable-biocompatible poly(DL-lactide-co-glycolide) polymeric matrix, wherein said antigenic synthetic peptide is present in an amount of 0.1% to 1% by weight of said vaccine and said polymer is present in an amount of 99% to 99.9% by weight of said vaccine, wherein the CFA/I pilus protein T-cell epitopes consist of the amino acid sequence:
-
(SEQ ID NO;
1) [4] (Asn-Ile-Thr-Val-Thr-Ala-Ser-Val-Asp-Pro),(SEQ ID NO;
11) (Gly-Asn-Tyr-Ser-Gly-Val-Val-Ser-Leu-Val), and mixtures thereof. - View Dependent Claims (4, 5, 6)
-
Specification